SCHEMBL30587044

CC(=O)N[C@H]1[C@H](OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2NC(C)=O)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2NC(C)=O)NC(=O)OCc2ccccc2)O[C@H](CO)[C@H](O)[C@@H]1O

nearest known ligand 0.75

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK1	P28482	1/20	0.46

▸	B4GALT1	P15291	1/20	0.41

▸	MDK	P21741	1/20	0.41

▸	MEN1	O00255	1/20	0.40

▸	KMT2A	Q03164	1/20	0.40

▸	LGALS3	P17931	2/20	0.40

▸	LGALS8	O00214	1/20	0.40

▸	LGALS4	P56470	1/20	0.40

▸	ANPEP	P15144	2/20	0.38

▸	PDCD1	Q15116	1/20	0.38

▸	CD274	Q9NZQ7	1/20	0.38

▸	HRAS	P01112	1/20	0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30634609	1.00	MAPK1 (0.46)	MAPK1B4GALT1MDKMEN1KMT2A
SCHEMBL26350758	0.97	MAPK1 (0.43)	MAPK1B4GALT1MDKMEN1KMT2A
SCHEMBL26349835	0.91	MAOB (0.39)	LGALS8
SCHEMBL24961301	0.89	MAPK1 (0.49)	MAPK1B4GALT1MDKMEN1KMT2A
SCHEMBL21763637	0.86	MAPK1 (0.56)	MAPK1B4GALT1MDKMEN1KMT2A
SCHEMBL18333352	0.86	MDK (0.42)	MAPK1B4GALT1MDKMEN1KMT2A
SCHEMBL29959492	0.85	LMNA (0.50)	MAPK1KMT2A
SCHEMBL26951859	0.85	LMNA (0.50)	MAPK1KMT2A
SCHEMBL25460389	0.85	LMNA (0.50)	MAPK1KMT2A
SCHEMBL16217756	0.85	LMNA (0.50)	MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230303618-A1	TRIPTOLIDE CONJUGATES AND USES THEREOF	REYOUNG CORPORATION (US)	2023-09-28	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230303618-A1	TRIPTOLIDE CONJUGATES AND USES THEREOF	TLR9, XIAP, ENPP2	MAPK1 4505/4885B4GALT1 626/4885MDK 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.